LifeSci Capital Initiates Coverage On Veradermics with Outperform Rating, Announces Price Target of $135

Benzinga Newsdesk www.benzinga.com Positive 66.2%

Neg 0% Neu 0% Pos 66.2%

LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outperform rating and announces Price Target of $135.